AC
ELEV

Armistice Capital’s Elevation Oncology ELEV Stock Holding History

Armistice Capital’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-750,000
Closed -$497K – 325
2023
Q3 		$497K Sell
750,000
-1,646,000
-69% -$1.66M 0.01% 168
2023
Q2 		$3.64M Buy
+2,396,000
New +$6.32M 0.05% 126

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Armistice Capital's ELEV Position: Q4 2023 in Review

Armistice Capital sold out of Elevation Oncology (ELEV) in Q4 2023, closing a stake of 750,000 shares — an estimated $497K sold.

Armistice Capital first reported a position in ELEV in Q2 2023 and held it in 2 quarters. The position peaked at $3.64M in Q2 2023. 32 funds tracked by Wall St. Rank hold ELEV as of Q4 2023.

  • Armistice Capital reported no remaining Elevation Oncology position as of Q4 2023 after selling out during the quarter.
  • Armistice Capital sold 750,000 Elevation Oncology shares in Q4 2023, an estimated $497K.
  • Armistice Capital first reported a position in Elevation Oncology in Q2 2023 and held it in 2 quarters.
  • Armistice Capital's Elevation Oncology position peaked at $3.64M in Q2 2023.
  • 32 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.